Neumora Therapeutics

Yahoo Finance • 23 days ago

Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511

Neumora Therapeutics Inc (NASDAQ:NMRA) is among the best NASDAQ penny stocks to buy according to analysts. Presenting at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, Neumora executives shared additional data from th... Full story

Yahoo Finance • 2 months ago

3 Promising Penny Stocks With Market Caps Up To $400M

The U.S. stock market kicked off February with a strong performance, as major indexes like the Dow Jones and S&P 500 posted significant gains. Amidst this backdrop of optimism, investors are exploring various opportunities across different... Full story

Yahoo Finance • 3 months ago

Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers

(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% t... Full story

Yahoo Finance • 5 months ago

Neumora to initiate phase 1 study of oral obesity pill

[Tape measure with diet pills on a blue background] CatLane * Neumora Therapeutics (NASDAQ:NMRA [https://seekingalpha.com/symbol/NMRA]) plans to begin a phase 1 study of its oral NLRP3 inhibitor NMRA-215 for diet-induced obesity in Q1 2... Full story

Yahoo Finance • 5 months ago

October 2025's Top Penny Stocks To Watch

As of October 2025, the U.S. stock market has been reaching new heights, with major indices such as the Dow Jones Industrial Average crossing significant milestones following a favorable inflation report. In this context, penny stocks—ofte... Full story

Yahoo Finance • 5 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical studies conducted in multiple species, inc... Full story

Yahoo Finance • 5 months ago

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model 

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class weight loss of up to 26% in combination with semaglutide Class-leading weight loss driven b... Full story

Yahoo Finance • 6 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27

WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action fo... Full story

Yahoo Finance • 6 months ago

Apple initiated, Hershey upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Arete upgraded Baidu (BIDU) to Buy fro... Full story

Yahoo Finance • 8 months ago

Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215

Earnings Call Insights: Neumora Therapeutics (NMRA) Q2 2025 MANAGEMENT VIEW * Paul L. Berns, Chief Executive Officer, stated that Neumora "prioritized obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibi... Full story

Yahoo Finance • 8 months ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-st... Full story

Yahoo Finance • 8 months ago

Neumora Therapeutics soars 68% following InvestingPro's June Fair Value signal

InvestingPro’s Fair Value model recently demonstrated its effectiveness by identifying a significant opportunity in Neumora Therapeutics (NASDAQ:NMRA), a clinical-stage biopharmaceutical company. The model’s June 13 analysis flagged NMRA... Full story

Yahoo Finance • 9 months ago

H.C. Wainwright reiterates Buy rating on Neumora Therapeutics stock

Investing.com - H.C. Wainwright has reiterated its Buy rating and $18.00 price target on Neumora Therapeutics (NASDAQ:NMRA) following the company’s selection of a new lead M4 PAM candidate for schizophrenia treatment. According to Invest... Full story

Yahoo Finance • 9 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits WATERTOWN, Mass., July 09, 2025 (... Full story

Yahoo Finance • 10 months ago

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareh... Full story

Yahoo Finance • 11 months ago

Galapagos Announces Executive Leadership Updates

Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans... Full story

Yahoo Finance • 11 months ago

Galapagos kondigt wijzigingen aan in uitvoerend leiderschap

De heer Henry Gosebruch benoemd door de Raad van Bestuur van Galapagos als oprichtend CEO van het nieuw opgerichte SpinCo Dr. Paul Stoffels, Voorzitter en CEO van Galapagos, is van plan in pensioen te gaan als CEO na benoeming van een opv... Full story

Yahoo Finance • 12 months ago

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. (... Full story

Yahoo Finance • 12 months ago

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA... Full story

Yahoo Finance • 12 months ago

Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 – NMRA

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: T... Full story